Capricor Therapeutics (CAPR) Depreciation & Amortization (CF) (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Depreciation & Amortization (CF) of $534670.0 for Q1 2026, up 31.87% year-over-year from $405450.0 in Q1 2025, and up 6.38% quarter-over-quarter from $502587.0 in Q4 2025.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $534670.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 31.87% year-over-year to $534670.0; the TTM figure through Mar 2026 stood at $2.0 million (up 34.62% YoY), while the FY2025 annual figure was $1.9 million, up 32.54% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $534670.0, up from $502587.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $534670.0 in Q1 2026, with the low at $92490.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $331406.0 (2024), against an average of $320643.4.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) jumped 148.78% in 2023, then advanced 22.14% in 2024.
- Capricor Therapeutics' Depreciation & Amortization (CF) stood at $191602.0 in 2022, then surged by 60.55% to $307608.0 in 2023, then gained by 22.14% to $375705.0 in 2024, then jumped by 33.77% to $502587.0 in 2025, then rose by 6.38% to $534670.0 in 2026.
- Business Quant data shows CAPR's Depreciation & Amortization (CF) at $534670.0 in Q1 2026, $502587.0 in Q4 2025, and $494726.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - | 561,845.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 561,845.00 |
| Mar 31, 2026 | 534,670.00 |
| Dec 31, 2025 | 502,587.00 |
| Sep 30, 2025 | 494,726.00 |
| Jun 30, 2025 | 486,278.00 |
| Mar 31, 2025 | 405,450.00 |
| Dec 31, 2024 | 375,705.00 |
| Sep 30, 2024 | 361,168.00 |
| Jun 30, 2024 | 356,935.00 |
| Mar 31, 2024 | 331,406.00 |
| Dec 31, 2023 | 307,608.00 |
| Sep 30, 2023 | 276,471.00 |
| Jun 30, 2023 | 254,702.00 |
| Mar 31, 2023 | 230,101.00 |
| Dec 31, 2022 | 191,602.00 |
| Sep 30, 2022 | 137,028.00 |
| Jun 30, 2022 | 112,011.00 |
| Mar 31, 2022 | 92,490.00 |
| Dec 31, 2021 | 78,645.00 |
| Sep 30, 2021 | 64,720.00 |